Related Experiment Video
Updated: Jun 18, 2026
Acupoint Catgut Embedding for Treatment of Chronic Pelvic Pain Due to the Sequelae of Pelvic Inflammatory Disease
Published on: May 3, 2024
Current concepts in managing pelvic inflammatory disease
1Department of Gynecology, Obstetrics & Reproduction, Maternite Regionale Universitaire of NANCY, Nancy, France. p.judlin@maternite.chu-nancy.fr
Purpose Of Review:
The management of pelvic inflammatory disease (PID) has significantly changed during the last two decades. Moreover, some recent bacterial findings have led to recent changes in this management.
Recent Findings:
Most cases of PID are mild-to-moderate uncomplicated forms that can be treated as outpatients. Apart from Chlamydia trachomatis and Neisseria gonorrhoeae, other pathogens such as Mycoplasma genitalium and bacterial vaginosis (BV)-associated bacteria are playing a significant role in PID and thus must be reckoned with. Moreover, gonococci have increasingly become resistant to the majority of antibiotics. This has led to a universal recommendation to treat N. gonorrhoeae infections with ceftriaxone. A few recent clinical trials have shown that quinolones and azithromycin (with metronidazole) are the best therapeutic options to treat uncomplicated PID.
Summary:
The management of PID nowadays must take into account the role of pathogens such as M. genitalium, BV-associated bacteria and multiresistant gonococci.
Insights
Pelvic inflammatory disease (PID) management has evolved, recognizing new pathogens like Mycoplasma genitalium and BV-associated bacteria. Current treatment focuses on ceftriaxone for gonorrhea and quinolones or azithromycin for uncomplicated PID.
Area of Science:
- Reproductive Health
- Infectious Diseases
- Microbiology
Background:
- Pelvic inflammatory disease (PID) management has undergone significant evolution over the past two decades.
- Recent advancements in understanding causative pathogens have prompted changes in clinical guidelines.
Purpose of the Study:
- To review the current management strategies for pelvic inflammatory disease (PID).
- To highlight the impact of recent bacterial findings on PID treatment protocols.
Main Methods:
- Review of recent clinical trials and epidemiological data on PID pathogens.
- Analysis of antibiotic resistance patterns for common PID-causing bacteria.
- Evaluation of current treatment recommendations for uncomplicated PID.
Main Results:
- Most PID cases are mild-to-moderate and treatable in outpatient settings.
- Emerging pathogens like Mycoplasma genitalium and bacterial vaginosis (BV)-associated bacteria are significant contributors to PID.
- Increasing antibiotic resistance in Neisseria gonorrhoeae necessitates specific treatment approaches, with ceftriaxone as a universal recommendation.
- Recent trials suggest quinolones and azithromycin (with metronidazole) are optimal for uncomplicated PID.
Conclusions:
- Modern PID management must incorporate the roles of Mycoplasma genitalium, BV-associated bacteria, and multidrug-resistant Neisseria gonorrhoeae.
- Treatment strategies need to adapt to evolving pathogen profiles and antibiotic resistance.
Related Concept Videos
01:17Urinary Tract Infection IV: Nursing Management
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:29Endocarditis IV: Nursing Management
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...